VIPR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7111488	0.74	20/20
SCHEMBL7111492	0.74	20/20
SCHEMBL6464911	0.69	20/20
SCHEMBL7108477	0.65	20/20
SCHEMBL7110730	0.66	19/20
Hydrochloric Acid (SCHEMBL7108282)	0.65	19/20
SCHEMBL6469322	0.64	19/20
SCHEMBL6468238	0.64	19/20
SCHEMBL6419552	0.63	19/20
SCHEMBL6467931	0.63	19/20
SCHEMBL6464846	0.62	19/20
SCHEMBL7111515	0.62	19/20
SCHEMBL7108294	0.61	19/20
SCHEMBL6465865	0.61	19/20
SCHEMBL6465749	0.60	19/20
SCHEMBL6464166	0.58	19/20
SCHEMBL6464171	0.58	19/20
SCHEMBL6465753	0.58	19/20
SCHEMBL6465875	0.57	19/20
SCHEMBL6465881	0.57	19/20

Clinical trials — most relevant to VIPR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19	PHASE3	WITHDRAWN
Comp Granisetron Midazolam Comb in Lap Children	PHASE3	UNKNOWN
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	PHASE1/PHASE2	RECRUITING
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure	PHASE2	COMPLETED
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake	PHASE2	RECRUITING
Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women	PHASE1	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients	nan	COMPLETED
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology	nan	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers	nan	COMPLETED
Vasoactive Intestinal Peptide in COPD	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache	nan	COMPLETED
NDPH Biomarker Study in Children and Adolescents	nan	COMPLETED
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers	nan	COMPLETED
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)	nan	COMPLETED
Gastrointestinal Hormonal Regulation of Obesity	nan	COMPLETED
Neuropeptides in the Humane Intra- og Extracerebral Circulation.	nan	COMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling	nan	COMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis	nan	COMPLETED
The Effect of Vasopressin on Glucose Regulation	nan	COMPLETED
The Lean Living Study	nan	COMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
Magnetic Resonance Imaging of Motility in Crohn's 2	nan	COMPLETED
Eating Behaviour in Crohn's Disease	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a VIPR2 binder may also engage these)

Protein	Name	Similarity
P30083	—	1.000	P30083 →
P35000	—	1.000	P35000 →
GLP1R	Glucagon-like peptide 1 receptor	1.000	landscape →
Q9IB86	—	1.000	Q9IB86 →
P41588	—	1.000	P41588 →
SCTR	Secretin receptor	0.999	landscape →
Q28992	—	0.998	Q28992 →
O35659	—	0.997	O35659 →
Q63118	—	0.997	Q63118 →
Q5FWI2	—	0.996	Q5FWI2 →
P32082	—	0.996	P32082 →
P23811	—	0.996	P23811 →
Q68EK2	—	0.996	Q68EK2 →
Q29627	—	0.996	Q29627 →
VIPR1	Vasoactive intestinal polypeptide receptor 1	0.995	landscape →
O46502	—	0.995	O46502 →
P97751	—	0.994	P97751 →
Q02644	—	0.993	Q02644 →
P32301	—	0.992	P32301 →
P35464	—	0.992	P35464 →
O08893	—	0.991	O08893 →
GCGR	Glucagon receptor	0.991	landscape →
P79222	—	0.991	P79222 →
P34999	—	0.990	P34999 →
Q61606	—	0.990	Q61606 →
GHRHR	Growth hormone-releasing hormone receptor	0.989	landscape →
Q0P4Y4	—	0.988	Q0P4Y4 →
Q0P543	—	0.988	Q0P543 →
O95838	—	0.988	O95838 →
P70205	—	0.987	P70205 →